Medulloblastoma (MB) and related CNS primitive neuroectodermal tumors (PNETs) are the most common pediatric malignant brain tumors and major source of neurological morbidity and mortality in children. Despite the importance of this tumor and recent gains in developmental neurobiology and neurogenesis, the biology of MB and PNETs is poorly understood, treatment progress has stalled, and future advances will be contingent upon a greater understanding of the biology of these tumors, To address these problems, this Program Project aims to identify and characterize the role of neurotrophic growth factors and their cognate receptors (e.g., tropomyosin receptor kinases, TRK) in the regulation of proliferation, differentiation, and cell death in PNETs, and to exploit advances in knowledge of these processes to identify new prognostic information and therapeutic strategies. These overall objectives will be accomplished by the following projects. The first Project will produce TRK-specific monoclonal antibodies, and use these to characterized TRK expression and its functional and clinical significance in MB and related CNS PNETs. The second Project will evaluate the expression and function of TRK-B and -C in medulloblastoma and neuroblastoma, a peripheral nervous system PNET with many parallels to MB. The third Project will examine the role of tyrosine kinase signal transduction intermediates in the regulation of tumorigenesis and proliferation in MB. The fourth Project will focus on experimental therapies for leptomeningeal dissemination of MB, including new strategies which target receptor tyrosine kinases or their signal transduction pathways. A rich network of interrelationships links these projects and the thematic focus adds to the internal cohesiveness of this Program Project. Its feasibility is further enhanced by the addition of the New York University Neuro-Oncology Program to this Program Project. Medulloblastoma represents a robust model from which we may advance our understanding of normal and aberrant neurogenesis. Accordingly, the observations and results from Projects in this Program will have important implications for our understanding of developmental neurobiology and the biology and treatment of other primary brain tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS034514-05
Application #
6188219
Study Section
Special Emphasis Panel (SRC (12))
Program Officer
Jacobs, Tom P
Project Start
1996-09-10
Project End
2002-04-30
Budget Start
2000-05-01
Budget End
2002-04-30
Support Year
5
Fiscal Year
2000
Total Cost
$1,266,264
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ho, Ruth; Eggert, Angelika; Hishiki, Tomoro et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62:6462-6
Eggert, A; Grotzer, M A; Zuzak, T J et al. (2002) Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. Eur J Cancer 38:92-8
Geoerger, B; Kerr, K; Tang, C B et al. (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-32
Evans, A E; Kisselbach, K D; Liu, X et al. (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol 36:181-4
Eggert, A; Grotzer, M A; Ikegaki, N et al. (2001) Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 19:689-96
Huber, H; Eggert, A; Janss, A J et al. (2001) Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 37:2064-72
Eggert, A; Ikegaki, N; Liu, X G et al. (2001) TrkA signal transduction pathways in neuroblastoma. Med Pediatr Oncol 36:108-10
Damodar Reddy, C; Marwaha, S; Patti, R et al. (2001) Role of MAP kinase pathways in primitive neuroectodermal tumors. Anticancer Res 21:2733-8
Grotzer, M A; Hogarty, M D; Janss, A J et al. (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-33
Tang, X X; Evans, A E; Zhao, H et al. (2001) Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36:80-2

Showing the most recent 10 out of 41 publications